company background image
PHARM logo

Pharming Group ENXTAM:PHARM Stock Report

Last Price

€1.01

Market Cap

€677.1m

7D

-2.2%

1Y

-19.7%

Updated

27 Mar, 2024

Data

Company Financials +

Pharming Group N.V.

ENXTAM:PHARM Stock Report

Market Cap: €677.1m

PHARM Stock Overview

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally.

PHARM fundamental analysis
Snowflake Score
Valuation5/6
Future Growth4/6
Past Performance0/6
Financial Health6/6
Dividends0/6

Pharming Group N.V. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Pharming Group
Historical stock prices
Current Share Price€1.01
52 Week High€1.31
52 Week Low€0.93
Beta0.74
1 Month Change-3.90%
3 Month Change-3.54%
1 Year Change-19.67%
3 Year Change-8.65%
5 Year Change20.23%
Change since IPO-98.93%

Recent News & Updates

Revenues Working Against Pharming Group N.V.'s (AMS:PHARM) Share Price

Feb 14
Revenues Working Against Pharming Group N.V.'s (AMS:PHARM) Share Price

Recent updates

Revenues Working Against Pharming Group N.V.'s (AMS:PHARM) Share Price

Feb 14
Revenues Working Against Pharming Group N.V.'s (AMS:PHARM) Share Price

Health Check: How Prudently Does Pharming Group (AMS:PHARM) Use Debt?

Nov 11
Health Check: How Prudently Does Pharming Group (AMS:PHARM) Use Debt?

Pharming Group N.V. (AMS:PHARM) Shares Could Be 49% Below Their Intrinsic Value Estimate

Aug 23
Pharming Group N.V. (AMS:PHARM) Shares Could Be 49% Below Their Intrinsic Value Estimate

Health Check: How Prudently Does Pharming Group (AMS:PHARM) Use Debt?

Jun 20
Health Check: How Prudently Does Pharming Group (AMS:PHARM) Use Debt?

Is Pharming Group (AMS:PHARM) Using Too Much Debt?

Mar 16
Is Pharming Group (AMS:PHARM) Using Too Much Debt?

Pharming Group N.V.'s (AMS:PHARM) Intrinsic Value Is Potentially 41% Above Its Share Price

Feb 17
Pharming Group N.V.'s (AMS:PHARM) Intrinsic Value Is Potentially 41% Above Its Share Price

We Think Pharming Group (AMS:PHARM) Can Manage Its Debt With Ease

Dec 08
We Think Pharming Group (AMS:PHARM) Can Manage Its Debt With Ease

Is Pharming Group (AMS:PHARM) Using Too Much Debt?

Aug 05
Is Pharming Group (AMS:PHARM) Using Too Much Debt?

Pharming Group N.V. Just Missed EPS By 56%: Here's What Analysts Think Will Happen Next

Mar 21
Pharming Group N.V. Just Missed EPS By 56%: Here's What Analysts Think Will Happen Next

These Analysts Think Pharming Group N.V.'s (AMS:PHARM) Sales Are Under Threat

Mar 19
These Analysts Think Pharming Group N.V.'s (AMS:PHARM) Sales Are Under Threat

Is Pharming Group (AMS:PHARM) Using Too Much Debt?

Feb 20
Is Pharming Group (AMS:PHARM) Using Too Much Debt?

Pharming Group N.V.'s (AMS:PHARM) Intrinsic Value Is Potentially 40% Above Its Share Price

Oct 29
Pharming Group N.V.'s (AMS:PHARM) Intrinsic Value Is Potentially 40% Above Its Share Price

Pharming Group (AMS:PHARM) Seems To Use Debt Quite Sensibly

Jun 03
Pharming Group (AMS:PHARM) Seems To Use Debt Quite Sensibly

Increases to CEO Compensation Might Be Put On Hold For Now at Pharming Group N.V. (AMS:PHARM)

May 12
Increases to CEO Compensation Might Be Put On Hold For Now at Pharming Group N.V. (AMS:PHARM)

Is Pharming Group N.V.'s (AMS:PHARM) Recent Performance Tethered To Its Attractive Financial Prospects?

Mar 15
Is Pharming Group N.V.'s (AMS:PHARM) Recent Performance Tethered To Its Attractive Financial Prospects?

Pharming Group (AMS:PHARM) Seems To Use Debt Rather Sparingly

Feb 15
Pharming Group (AMS:PHARM) Seems To Use Debt Rather Sparingly

We Think Pharming Group's (AMS:PHARM) Statutory Profit Might Understate Its Earnings Potential

Jan 28
We Think Pharming Group's (AMS:PHARM) Statutory Profit Might Understate Its Earnings Potential

Did You Miss Pharming Group's (AMS:PHARM) Whopping 350% Share Price Gain?

Jan 05
Did You Miss Pharming Group's (AMS:PHARM) Whopping 350% Share Price Gain?

Shareholder Returns

PHARMNL BiotechsNL Market
7D-2.2%4.3%2.7%
1Y-19.7%-2.7%19.3%

Return vs Industry: PHARM underperformed the Dutch Biotechs industry which returned -1.1% over the past year.

Return vs Market: PHARM underperformed the Dutch Market which returned 21.7% over the past year.

Price Volatility

Is PHARM's price volatile compared to industry and market?
PHARM volatility
PHARM Average Weekly Movement5.1%
Biotechs Industry Average Movement7.4%
Market Average Movement3.7%
10% most volatile stocks in NL Market8.0%
10% least volatile stocks in NL Market2.3%

Stable Share Price: PHARM has not had significant price volatility in the past 3 months.

Volatility Over Time: PHARM's weekly volatility (5%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
n/a332Simon de Vrieshttps://www.pharming.com

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company’s commercialized product is RUCONEST, a plasma-free rhC1INH protein replacement therapy for the treatment acute hereditary angioedema (HAE) attacks. It also engages in the development of leniolisib for the treatment of activated phosphoinositide 3-kinase delta syndrome; OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE; and alpha-glucosidase therapy for the treatment of Pompe and fabry diseases.

Pharming Group N.V. Fundamentals Summary

How do Pharming Group's earnings and revenue compare to its market cap?
PHARM fundamental statistics
Market cap€677.11m
Earnings (TTM)-€9.35m
Revenue (TTM)€226.60m

3.0x

P/S Ratio

-72.4x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
PHARM income statement (TTM)
RevenueUS$245.32m
Cost of RevenueUS$25.21m
Gross ProfitUS$220.10m
Other ExpensesUS$230.22m
Earnings-US$10.12m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

Apr 04, 2024

Earnings per share (EPS)-0.015
Gross Margin89.72%
Net Profit Margin-4.12%
Debt/Equity Ratio63.2%

How did PHARM perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.